Literature DB >> 2016123

Anti-CD9 antibodies augment neutrophil adherence to endothelium.

K D Forsyth1.   

Abstract

Anti-CD9 antibodies which bind to the CD9 (p24) antigen are known to induce platelet and pre-B-cell aggregation. We show here that human endothelium expresses the CD9 antigen, and anti-CD9 antibodies incubated with endothelium induce a rapid increase in adhesion of neutrophils to endothelium by an action on the endothelial cell. This augmented adhesion is not mediated by glycoprotein IIb/IIIa or by the leucocyte integrins. Binding of anti-CD9 antibody to CD9 induces shedding of the CD9/anti-CD9 complex off the endothelial cell in a time-dependent manner. It is likely that CD9 binding to its ligand induces an activation event within the endothelial cell, resulting in surface expression of a pre-formed adhesive ligand for the neutrophil, or an activation change to a constitutively expressed ligand to render it functional.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016123      PMCID: PMC1384499     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Neutrophil adherence to human endothelium in vitro occurs by CDw18 (Mo1, MAC-1/LFA-1/GP 150,95) glycoprotein-dependent and -independent mechanisms.

Authors:  G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

2.  The p24 leucocyte membrane antigen: modulation associated with lymphocyte activation and differentiation.

Authors:  H Zola; V Furness; S Barclay; H Zowtyj; M Smith; J V Melo; S H Neoh; J Bradley
Journal:  Immunol Cell Biol       Date:  1989-02       Impact factor: 5.126

Review 3.  Leukocyte adhesion deficiency: molecular basis and functional consequences.

Authors:  A Fischer; B Lisowska-Grospierre; D C Anderson; T A Springer
Journal:  Immunodefic Rev       Date:  1988

4.  Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation.

Authors:  G I Johnston; R G Cook; R P McEver
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

5.  Leukocyte adherence-related glycoproteins LFA-1, Mo1, and p150,95: a new group of monoclonal antibodies, a new disease, and a possible opportunity to understand the molecular basis of leukocyte adherence.

Authors:  J I Gallin
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

6.  Expression of a 26,000-dalton glycoprotein on activated human T cells.

Authors:  T Hercend; L M Nadler; J M Pesando; E L Reinherz; S F Schlossman; J Ritz
Journal:  Cell Immunol       Date:  1981-10       Impact factor: 4.868

7.  A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIB-IIIA complex.

Authors:  D Jones; J Fritschy; J Garson; T J Nokes; J T Kemshead; R M Hardisty
Journal:  Br J Haematol       Date:  1984-08       Impact factor: 6.998

8.  Evidence that monoclonal antibodies against CD9 antigen induce specific association between CD9 and the platelet glycoprotein IIb-IIIa complex.

Authors:  J R Slupsky; J G Seehafer; S C Tang; A Masellis-Smith; A R Shaw
Journal:  J Biol Chem       Date:  1989-07-25       Impact factor: 5.157

9.  Expression of the non-T ALL-associated p24 antigen on leukaemic blasts from patients with ANLL.

Authors:  L K Ashman; D White; H Zola; G W Dart
Journal:  Leuk Res       Date:  1987       Impact factor: 3.156

10.  P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody.

Authors:  J H Kersey; T W LeBien; C S Abramson; R Newman; R Sutherland; M Greaves
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  8 in total

1.  Antibody cross-linking of human CD9 and the high-affinity immunoglobulin E receptor stimulates secretion from transfected rat basophilic leukaemia cells.

Authors:  A Higginbottom; I Wilkinson; B McCullough; F Lanza; D O Azorsa; L J Partridge; P N Monk
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

Review 2.  Tetraspanins and vascular functions.

Authors:  Feng Zhang; Jayaprakash Kotha; Lisa K Jennings; Xin A Zhang
Journal:  Cardiovasc Res       Date:  2009-02-27       Impact factor: 10.787

3.  Astrocyte growth, reactivity, and the target of the antiproliferative antibody, TAPA.

Authors:  E E Geisert; L Yang; M H Irwin
Journal:  J Neurosci       Date:  1996-09-01       Impact factor: 6.167

4.  An antibody to the tetraspan membrane protein CD9 promotes neurite formation in a partially alpha3beta1 integrin-dependent manner.

Authors:  S A Banerjee; M Hadjiargyrou; P H Patterson
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

5.  Transmembrane 4 superfamily protein CD151 (PETA-3) associates with beta 1 and alpha IIb beta 3 integrins in haemopoietic cell lines and modulates cell-cell adhesion.

Authors:  S Fitter; P M Sincock; C N Jolliffe; L K Ashman
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

6.  Establishing clonal cell lines with endothelial-like potential from CD9(hi), SSEA-1(-) cells in embryonic stem cell-derived embryoid bodies.

Authors:  Qizhou Lian; Keng Suan Yeo; Jianwen Que; Eileen Khia Way Tan; Fenggang Yu; Yijun Yin; Manuel Salto-Tellez; Reida Menshawe El Oakley; Sai-Kiang Lim
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

7.  The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes.

Authors:  U Martin; D Bock; L Arseniev; M A Tornetta; R S Ames; W Bautsch; J Köhl; A Ganser; A Klos
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

8.  Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions.

Authors:  M Yáñez-Mó; A Alfranca; C Cabañas; M Marazuela; R Tejedor; M A Ursa; L K Ashman; M O de Landázuri; F Sánchez-Madrid
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.